Point of Care/ Rapid Diagnostics Market worth $75.5 billion by 2027

The Global Point of Care Diagnostics Market in terms of revenue is expected to be worth $75.5 billion by 2027, growing at a CAGR of 10.7% in the upcoming years.

The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. In the latest edition of the report, new product and sample segments have been added. The updated report will have a segment dedicated to providing a detailed understanding of different types of point of care products and samples. The growth of this market can be attributed to the high prevalence of respiratory diseases such as influenza, cardiac diseases, and infectious diseases (where point of care tests can greatly improve the management of these diseases, especially in developing countries where access to timely medical care is a challenge and the healthcare infrastructure is antiquated and sparse). Furthermore, with the increasing availability of point of care testing products via online platforms, supportive government policies, and an increase in the number of CLIA-waived point of care tests, healthcare decentralisation and greater investments and funding for product development are expected to accelerate the growth of the market in the coming years.

Download PDF Brochure:

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=106829185

Point of Care and Rapid Diagnostics Market Dynamics

Drivers: increasing prevalence of infectious diseases

Point of care tests with high sensitivity and specificity allow for rapid diagnosis and treatment of these highly infectious diseases. The prevalence of infectious diseases such as HIV, hepatitis, influenza, and tuberculosis is likely to boost the demand for point of care diagnostics for the rapid detection of infectious diseases. Listed below are important statistics related to major infectious diseases in developing countries:

According to the National Aids Control Organization (NACO), in 2021, approximately 2.40 million people in India were infected with HIV. Of the total HIV-infected population, 45% were women, and 2% were children under the age of 12.
According to the WHO Global TB Report 2021, of the 1.7 billion global population infected with TB, around 587 million people with TB reside in Southeast Asia (SEA).

Opportunities: Point of care tests with multiplexing capabilities.

Companies are trying to develop Point of care devices that can run multiple analytes on a single device. These devices can simultaneously measure multiple analytes on the same cartridge, which is known as multiplexing. Multiplex Point of care tests offer several advantages over widely adopted singleplex tests, such as increased efficiency at lower costs, greater output per sample, and higher throughput. These benefits will aid in the development of more precise and detailed diagnostics as well as the advancement of personalised medicine. Some examples of multiplexed devices include: The Triage 8 Panel for Drugs of Abuse from Alere is an immunoassay that determines the major metabolites of drugs of abuse and provides results in 10 minutes. The commercialization of such cost-effective and advanced multiplex Point of care tests will offer new growth opportunities for market players.

Restraints: pricing pressure owing to reimbursement cuts and budget constraints.

The pricing pressure due to reimbursement cuts and a lack of sufficient budgets has impacted the growth of the global market. In France, all the cost of patient care is rolled into one prospective payment under the Diagnosis Related Group (DRG) system, making reimbursement a negligible factor. In the country, the reimbursement for diabetes technologies in outpatient settings is based on a tariff system.

Moreover, the expenditure on general-use medical devices is reported to be stagnating owing to the decrease in the number of healthcare products eligible for reimbursement, making it a challenging factor for manufacturers to support prices as competition intensifies. This factor is expected to pose a key challenge to the growth of the global market in the coming years.

Request Free Sample Pages:

https://www.marketsandmarkets.com/requestsampleNew.asp?id=106829185

In 2021, the Glucose Monitoring Product segment accounted for a sizable portion of the global Point of Care Diagnostics industry by product type.

The rising prevalence of diabevtes and increased patient awareness about the availability of point of care testing in the market are anticipated to propel the demand for glucose monitoring products during the forecast period. According to the IDF Diabetes Atlas, the number of people living with diabetes will increase from 425 million in 2017 to 642 million by 2040.

The number of companies focusing on the development of innovative self-monitoring glucose meters, such as Medtronic's Guardian Sensor 3—a diagnostic chip that automatically monitors health—and Roche's Accu-Chek Blood Glucose Monitoring System with wireless connectivity and app support—is anticipated to promote the growth potential of this segment in the coming years.

The lateral flow assays segment, by platform type, accounted for the largest share of the global point of care diagnostics market in 2021.

The rapid adoption of LFA testing products in home care settings, the rising focus of players on the development of innovative LFA-based point of care devices, and the increasing awareness about the advantages of lateral flow assay-based point of care tests as a replacement for lengthy laboratory procedures and the lower cost associated with this procedure over conventional laboratory procedures are anticipated to boost the growth of the lateral flow assays segment during the forecast period.

The home care and self-testing segments are expected to have the highest CAGR of the point of care diagnostics market in terms of end users.

The home care and self-testing segment is projected to register the highest CAGR during the forecast period. The end users in this segment include patients and emergency response personnel who use monitoring devices in home settings. Devices such as blood glucose meters, blood pressure monitors, HIV test kits, pregnancy test kits, and respiratory infection test kits are prominently used in this segment. Ease of usage, lower cost, and increasing accessibility of advanced self-testing kits are some of the key factors supporting the increased uptake of home testing kits. Several market players and government organisations are entering into joint ventures, partnerships, and collaborations to develop innovative and cost-effective products suitable for home care requirements, further supporting the growth of the home care and self-testing segments in the near future.

In July 2022, the Clinton Health Access Initiative (CHAI), MedAccess, and Wondfo Biotech Company entered into a strategic partnership with the aim of providing the HIV self-test for USD 1 to the public sector in low- and middle-income countries. This initiative will increase the accessibility of affordable HIV self-testing globally.

The Asia Pacific market is expected to grow at the highest CAGR of the point of care diagnostics market during the forecast period.

The market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America holds the largest share of the market. The rising prevalence of lifestyle diseases, government initiatives to support the wider adoption of point of care diagnostics, and the strong presence of key players in the region are anticipated to support the growth of the North American market.

Asia Pacific is projected to register the highest growth during the forecast period, owing to the rising number of hospitals and clinical diagnostics laboratories, growth in the patient population, the emergence of new rapid test kit manufacturers, increasing healthcare expenditure, and growing collaborations among players.

Prominent players in the point of care diagnostics market are Abbott Laboratories (US), Siemens Healthineers AG (Germany), Quidel Corporation (US), F. Hoffman-La Roche Ltd. (Switzerland), Danaher Corporation (US), Becton, Dickinson and Company (US), Chembio Diagnostics (US), EKF Diagnostics (UK), Trinity Biotech plc (Ireland), Instrumentation Laboratory (a Werfen Company) (US), Nova Biomedical (US), PTS Diagnostics (US), Sekisui Diagnostics (US), Thermo Fisher Scientific (US), and bioMérieux S.A. (France).

Recent Developments

In May 2022, QuantuMDx announced the launch of its new respiratory panel test; Q-POC™ SARS-CoV-2, Flu A/B RSV Assay.
In March 2022, Boditech Med entered in strategic partnership with Novo Integrated Sciences, Inc. with an aim to expand its biomarker based rapid testing product line across North America
In January 2022, Roche launched its Cobas Pulse System in select countries accepting the CE Mark. This is Roche Diagnostics’ newest generation of connected point-of-care solutions for professional blood glucose management.

Frequently Asked Questions (FAQ):

What is the projected market value of the global point of care diagnostics market?
What is the estimated growth rate (CAGR) of the global point of care diagnostics market for the next five years?
What does the current study of the point of care diagnostics market consist of?

Speak to Analyst:

https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=106829185

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Aashish Mehra

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA : 1-888-600-6441

Email: [email protected]

Research Insight: https://www.marketsandmarkets.com/ResearchInsight/point-of-care-diagnostic-market.asp

Visit Our Website: https://www.marketsandmarkets.com/

Content Source: https://www.marketsandmarkets.com/PressReleases/point-of-care-diagnostic.asp